Literature DB >> 8995739

Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators.

A Fogo1, J A Breyer, M C Smith, W H Cleveland, L Agodoa, K A Kirk, R Glassock.   

Abstract

African Americans have excess hypertension and end-stage renal disease presumed due to hypertension compared to Caucasians. The AASK was designed to examine the impact of antihypertensive therapies and two levels of blood pressure control on the rate of decline of GFR in African Americans with presumed hypertensive renal disease. During the pilot phase of the trial, eligible participants were requested to undergo renal biopsy to assess the underlying lesions in this population. Eighty-eight hypertensive (diastolic BP > 95 mm Hg) non-diabetic African American patients between the ages of 18 to 70 years, with GFR between 25 to 70 ml/min/1.73 m2 and without marked proteinuria were assessed for possible renal biopsy. Forty-three patients did not undergo renal biopsy due to refusal or contraindications. Adequate renal biopsies were obtained in 39 of the remaining 46 patients. Biopsy findings were analyzed and then compared to clinical parameters. The 39 patients studied, 29 men and 10 women, were on average 53.0 +/- 11.0 years old, and had a MAP of 109 +/- 15 mm Hg and GFR 51.7 +/- 13.6 ml/min/1.73 m2 (not significantly different from nonbiopsied patients). Thirty-eight of these 39 biopsies showed arteriosclerosis and/or arteriolosclerosis, severity on average 1.5 +/- 0.9 and 1.5 +/- 0.8, respectively on a 0 to 3+ scale. Interstitial fibrosis was moderate, 1.3 +/- 0.9 (0 to 3+ scale). Segmental glomerulosclerosis was present in five biopsies, and in one patient, biopsy and clinical findings were consistent with idiopathic focal segmental glomerulosclerosis. Additional lesions included mesangiopathic glomerulonephritis in one patient, basement membrane thickening suggestive of diabetic nephropathy in one, and cholesterol emboli in two cases. Arteriolar and arterial sclerosis were tightly linked, and correlated with interstitial fibrosis and the reciprocal of serum creatinine. Global glomerulosclerosis was extensive, involving on average 43 +/- 26% of glomeruli. The extent of this lesion did not correlate with degree of arteriolar or arterial thickening, but did correlate with systolic blood pressure (P = 0.0174), the reciprocal of serum creatinine (P = 0.0009), serum cholesterol (P = 0.0129) and interstitial fibrosis (P < 0.0001). These data underscore that renal biopsies in non-diabetic hypertensive African-Americans with mild to moderate renal insufficiency in the absence of marked proteinuria are overwhelmingly likely to show renal vascular lesions consistent with the clinical diagnosis of hypertensive nephrosclerosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8995739     DOI: 10.1038/ki.1997.29

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  76 in total

1.  Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans.

Authors:  Barry I Freedman; Carl D Langefeld; Mariana Murea; Lijun Ma; James D Otvos; Jolyn Turner; Peter A Antinozzi; Jasmin Divers; Pamela J Hicks; Donald W Bowden; Michael V Rocco; John S Parks
Journal:  Nephrol Dial Transplant       Date:  2011-09-19       Impact factor: 5.992

2.  The new era of APOL1-associated glomerulosclerosis.

Authors:  Barry I Freedman; Carl D Langefeld
Journal:  Nephrol Dial Transplant       Date:  2012-02-02       Impact factor: 5.992

Review 3.  Epidemiology of hypertensive kidney disease.

Authors:  Suneel Udani; Ivana Lazich; George L Bakris
Journal:  Nat Rev Nephrol       Date:  2010-11-16       Impact factor: 28.314

Review 4.  The African American Study of Kidney Disease: do these results indicate that 140/90 mm hg is good enough?

Authors:  Mahboob Rahman; Ashraf El-Meanawy; Joseph Romanello
Journal:  Curr Hypertens Rep       Date:  2005-10       Impact factor: 5.369

5.  Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans.

Authors:  Barry I Freedman; Pamela J Hicks; Meredith A Bostrom; Mary E Cunningham; Yongmei Liu; Jasmin Divers; Jeffrey B Kopp; Cheryl A Winkler; George W Nelson; Carl D Langefeld; Donald W Bowden
Journal:  Kidney Int       Date:  2009-01-28       Impact factor: 10.612

6.  Association of BP variability with mortality among African Americans with CKD.

Authors:  Ciaran J McMullan; George L Bakris; Robert A Phillips; John P Forman
Journal:  Clin J Am Soc Nephrol       Date:  2013-03-14       Impact factor: 8.237

7.  Association of histologic variants in FSGS clinical trial with presenting features and outcomes.

Authors:  Vivette D D'Agati; Joan M Alster; J Charles Jennette; David B Thomas; James Pullman; Daniel A Savino; Arthur H Cohen; Debbie S Gipson; Jennifer J Gassman; Milena K Radeva; Marva M Moxey-Mims; Aaron L Friedman; Frederick J Kaskel; Howard Trachtman; Charles E Alpers; Agnes B Fogo; Tom H Greene; Cynthia C Nast
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-06       Impact factor: 8.237

8.  Human nephrosclerosis triggers a hypoxia-related glomerulopathy.

Authors:  Matthias A Neusser; Maja T Lindenmeyer; Anton G Moll; Stephan Segerer; Ilka Edenhofer; Kontheari Sen; Daniel P Stiehl; Matthias Kretzler; Hermann-Josef Gröne; Detlef Schlöndorff; Clemens D Cohen
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

9.  Rapid progression to end-stage renal disease in young hypertensive African Americans with proteinuria.

Authors:  C I Obialo; K Hewan-Lowe
Journal:  J Natl Med Assoc       Date:  1998-11       Impact factor: 1.798

10.  Loss of GSTM1, a NRF2 target, is associated with accelerated progression of hypertensive kidney disease in the African American Study of Kidney Disease (AASK).

Authors:  Jamison Chang; Jennie Z Ma; Qing Zeng; Sylvia Cechova; Adam Gantz; Caroline Nievergelt; Daniel O'Connor; Michael Lipkowitz; Thu H Le
Journal:  Am J Physiol Renal Physiol       Date:  2012-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.